Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.

"Competing interests The authors declare no competing interests."

"Funding This work was supported by grants from Cancer Australia (ID 1138766 to LMB, DJL and MMC; ID 2001432 to LAS and LMB; ID 2011672 to ZDN); the Movember Foundation and the Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award (MRTA-3 to LMB and LAS). JAH is supported by a Beacon of Enlightenment PhD Scholarship from the University of Adelaide. CYM is supported by an Early-Career Research Fellowship awarded by the Prostate Cancer Foundation of Australia. LAS and LMB are supported by Principal Cancer Research Fellowships (PRF2919 and PRF1117, respectively) awarded by the Cancer Council’s Beat Cancer project on behalf of its donors, the State Government through the Department of Health and the Australian Government through the Medical Research Future Fund. Open Access funding enabled and organized by CAUL and its Member Institutions."